484 related articles for article (PubMed ID: 32945172)
41. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
Moussa M; Papatsoris A; Abou Chakra M; Dellis A
Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
[TBL] [Abstract][Full Text] [Related]
42. New and topics: enfortumab vedotin mechanisms of response and resistance in urothelial cancer - What do we understand so far?
Hoffman-Censits J; Lombardo K; McConkey D; Hahn NM; Bashir B; Kelly WK; Johnson B; Matoso A
Urol Oncol; 2021 Oct; 39(10):619-622. PubMed ID: 34148797
[TBL] [Abstract][Full Text] [Related]
43. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
[TBL] [Abstract][Full Text] [Related]
44. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
[TBL] [Abstract][Full Text] [Related]
45. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
46. Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort.
Zschäbitz S; Biernath N; Hilser T; Höllein A; Zengerling F; Cascucelli J; Paffenholz P; Seidl D; Lutz C; Schlack K; Kingreen D; Klümper N; Ivanyi P; von Amsberg G; Heers H; Roghmann F; Tauber RL; Cathomas R; Hofer L; Niegisch G; Klee M; Ehrenberg R; Hassler A; Hadaschik BA; Grünwald V; Darr C
Eur Urol Open Sci; 2023 Jul; 53():31-37. PubMed ID: 37441344
[TBL] [Abstract][Full Text] [Related]
47. FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
Chang E; Weinstock C; Zhang L; Charlab R; Dorff SE; Gong Y; Hsu V; Li F; Ricks TK; Song P; Tang S; Waldron PE; Yu J; Zahalka E; Goldberg KB; Pazdur R; Theoret MR; Ibrahim A; Beaver JA
Clin Cancer Res; 2021 Feb; 27(4):922-927. PubMed ID: 32962979
[TBL] [Abstract][Full Text] [Related]
48. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Filippi L; Schillaci O
Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
Wu S; Adamson AS
Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
[TBL] [Abstract][Full Text] [Related]
50. Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review.
Bantounou MA; Plascevic J; MacDonald L; Wong MC; O'Connell N; Galley HF
Curr Urol; 2023 Dec; 17(4):271-279. PubMed ID: 37994340
[TBL] [Abstract][Full Text] [Related]
51. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
[TBL] [Abstract][Full Text] [Related]
52. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
[TBL] [Abstract][Full Text] [Related]
53. Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin.
Shafique MA; Haseeb A; Siddiq MA; Mussarat A; Rangwala HS; Mustafa MS
Cancer Manag Res; 2023; 15():699-706. PubMed ID: 37485038
[TBL] [Abstract][Full Text] [Related]
54. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
Matsubara N; Yonese J; Kojima T; Azuma H; Matsumoto H; Powles T; Rosenberg JE; Petrylak DP; Matsangou M; Wu C; Campbell M; Yamashiro M
Cancer Med; 2023 Feb; 12(3):2761-2771. PubMed ID: 36052536
[TBL] [Abstract][Full Text] [Related]
55. Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
McGregor B; O'Donnell PH; Balar A; Petrylak D; Rosenberg J; Yu EY; Quinn DI; Heath EI; Campbell M; Hepp Z; McKay C; Steinberg J; Regnault A; Mazerolle F; Galsky MD
Eur Urol; 2022 May; 81(5):515-522. PubMed ID: 35168844
[TBL] [Abstract][Full Text] [Related]
56. Heterogeneity in
Chu CE; Sjöström M; Egusa EA; Gibb EA; Badura ML; Zhu J; Koshkin VS; Stohr BA; Meng MV; Pruthi RS; Friedlander TW; Lotan Y; Black PC; Porten SP; Feng FY; Chou J
Clin Cancer Res; 2021 Sep; 27(18):5123-5130. PubMed ID: 34108177
[TBL] [Abstract][Full Text] [Related]
57. Enfortumab Vedotin in urothelial cancer.
Alt M; Stecca C; Tobin S; Jiang DM; Sridhar SS
Ther Adv Urol; 2020; 12():1756287220980192. PubMed ID: 33447264
[TBL] [Abstract][Full Text] [Related]
58. C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.
Uchimoto T; Matsuda T; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Tsuchida S; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; ():. PubMed ID: 38807017
[TBL] [Abstract][Full Text] [Related]
59. Antibody-drug conjugates for the treatment of urothelial carcinoma.
Ravi P; McGregor BA
Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
[TBL] [Abstract][Full Text] [Related]
60. Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort study.
Taoka R; Kamada M; Izumi K; Tanimoto R; Daizumoto K; Hayashida Y; Uematsu K; Arai H; Sano T; Saito R; Hirama H; Kobayashi T; Honda T; Osaki Y; Abe Y; Naito H; Tohi Y; Matsuoka Y; Kato T; Okazoe H; Ueda N; Sugimoto M
Int J Clin Oncol; 2024 May; 29(5):602-611. PubMed ID: 38418804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
